CDKN1A and age-related macular degeneration: Surprisingly, in combination (P+Q) treatment significantly increases CDKN1A expression in AMD (4.09-fold ± 0.69, p-value = 0.001), Glc cybrids (5.05-fold ± 0.20, p-value = 0.014), and KC cybrids (4.41-fold ± 2.71, p-value = 0.027) (Figure 8a).